Skip to Content

Fosrenol FDA Approval History

FDA Approved: Yes (First approved October 26, 2004)
Brand name: Fosrenol
Generic name: lanthanum carbonate
Dosage form: Chewable Tablets
Company: Shire Pharmaceuticals Group plc
Treatment for: Hyperphosphatemia of Renal Failure

Fosrenol is a phosphate binder used to reduce high phosphorus levels in end-stage renal disease (ESRD) patients.

Development Timeline for Fosrenol

Oct 26, 2004ApprovalFosrenol Shire Pharmaceuticals Group plc - Treatment for Hyperphosphataemia in ESRD Patients
Jul 20, 2004Fosrenol: FDA Action Date Extended, US Launch Target Unaffected

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.